Investment
Features
FeesSafety
Academy
More
Pluang+

Compare FedEx Corporation (FDX) vs Smith & Nephew plc (SNN) Price & Performance

FedEx CorporationTrade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

FedEx Corporation vs Smith & Nephew plc — how do they compare? FedEx Corporation trades at $290.75 (market cap $69.04B), while Smith & Nephew plc trades at $27.3 (market cap $11.10B). The key difference: FedEx Corporation is far larger — about 6.2× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold FedEx Corporation for 87 Days and Smith & Nephew plc for 120 Days on average.

FDXSNN
Market Cap
$69.04B$11.10B
Volume
1,287,3671,051,703
Sector
IndustrialsHealth
52-Week High
$339.35$37.17
52-Week Low
$180.87$26.42
Typical Hold Time
87 Days120 Days
Enterprise Value
$98.68B$14.13B
Dividend Yield
1.67%2.95%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

FedEx Corporation

FedEx (FDX) trades at $289.04, showing minimal daily change. The stock exhibits a bearish technical signal with key support at $288 and resistance at $290. Fundamentally, the company maintains stable profitability with a net income margin of 4.68% and a P/E ratio of 15.73, while recent earnings beats in Q4 2025 and Q1 2026 highlight operational strength. Positive developments include a $300 million electric truck order and shareholder approval of executive compensation, though rising fuel prices present a near-term headwind.

The outlook for FDX is cautiously optimistic, supported by analyst consensus favoring a buy rating with a $307.55 price target. Investment appeal lies in its reasonable valuation and dividend yield, but risks include margin pressure from fuel costs, competitive intensity, and macroeconomic sensitivity. The stock's trajectory will likely hinge on execution of cost initiatives and freight demand trends.

Smith & Nephew plc

SNN trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue and net income have grown steadily, reaching $6.16B and $625M in 2025, respectively, with improving margins. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. However, cash flow volatility and mixed analyst sentiment pose challenges.

The stock presents a value opportunity with reasonable valuation ratios (P/E 18.34, P/S 1.85), but risks include competitive pressures and recent CFO departure. Analyst consensus is cautious, with 65% hold ratings. Upside depends on execution of growth initiatives amid market headwinds.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FDX
100% Buy0% Sell
Avg holding period · 87 Days
SNN

No sentiment data available yet.

About FedEx Corporation

FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.

Read more on FDX →

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN →